Transforming LGMD through Pioneering Gene Therapies

Myonexus Therapeutics is a clinical-stage gene therapy company

Leading Edge

Myonexus Therapeutics in the News

Myonexus Therapeutics Receives FDA Rare Pediatric Drug Designation for Pioneering Treatment of Limb Girdle Muscular Dystrophy Type 2E 150 150 Myonexus Therapeutics

Myonexus Therapeutics Receives FDA Rare Pediatric Drug Designation for Pioneering Treatment of Limb Girdle Muscular Dystrophy Type 2E

Rare Pediatric Disease Designation for MYO-101 Program Reflects Compelling Data and Enables Priority Review Voucher Eligibility NEW ALBANY, Ohio–(BUSINESS WIRE)–Myonexus Therapeutics, a clinical-stage gene therapy…

read more
Sarepta Therapeutics Announces Partnership with Myonexus Therapeutics for the Advancement of Multiple Gene Therapy Programs Aimed at Treating Distinct Forms of Limb-Girdle Muscular Dystrophies 150 150 Myonexus Therapeutics

Sarepta Therapeutics Announces Partnership with Myonexus Therapeutics for the Advancement of Multiple Gene Therapy Programs Aimed at Treating Distinct Forms of Limb-Girdle Muscular Dystrophies

— Sarepta strengthens position as a leader in gene therapy; expands rare disease franchise — — The program is designed, if successful, to offer first-ever corrective treatments…

read more
Myonexus Therapeutics Secures $2.5 Million Seed Financing to Clinically Advance Limb-Girdle Muscular Dystrophy (LGMD) Gene Therapies 150 150 Myonexus Therapeutics

Myonexus Therapeutics Secures $2.5 Million Seed Financing to Clinically Advance Limb-Girdle Muscular Dystrophy (LGMD) Gene Therapies

MYO-101 Phase 1/2a systemic gene therapy trial for LGMD2E to begin in early 2018 NEW ALBANY, Ohio–(BUSINESS WIRE)–Myonexus Therapeutics, Inc. (Myonexus), a clinical-stage biotechnology company…

read more


Our Mission

Myonexus Therapeutics is a clinical-stage gene therapy company developing first-ever corrective gene therapies for Limb-Girdle muscular dystrophies, debilitating rare diseases with no treatments.  

Positively Transforming Lives

Myonexus Therapeutics is developing first ever gene treatments for Limb-girdle muscular dystrophy (LGMD) types 2D, 2B, 2E, 2L, and 2C.